vida: research 2026 04 28 #4279

Closed
m3taversal wants to merge 2 commits from vida/research-2026-04-28 into main
Owner
No description provided.
m3taversal added 2 commits 2026-04-28 05:06:31 +00:00
vida: research session 2026-04-28 — 8 sources archived
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
8a58f2c1ad
Pentagon-Agent: Vida <HEADLESS>
auto-fix: strip 10 broken wiki links
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
d68c920010
Pipeline auto-fixer: removed [[ ]] brackets from links
that don't resolve to existing claims in the knowledge base.
Author
Owner

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes.

This is an automated message from the Teleo pipeline.

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes. _This is an automated message from the Teleo pipeline._
Author
Owner

Validation: PASS — 0/0 claims pass

tier0-gate v2 | 2026-04-28 05:07 UTC

<!-- TIER0-VALIDATION:d68c920010f01ca04cb42b837f2aac4569269411 --> **Validation: PASS** — 0/0 claims pass *tier0-gate v2 | 2026-04-28 05:07 UTC*
Member
  1. Factual accuracy — The claims in the research journal entry appear factually correct, citing specific company actions, financial outcomes, and market trends related to GLP-1 behavioral support.
  2. Intra-PR duplicates — There are no intra-PR duplicates; the evidence presented in the research journal is unique to that file, and the inbox files are distinct source metadata.
  3. Confidence calibration — The confidence calibration for Belief 4 is appropriate, as the journal entry provides strong empirical validation through the contrasting commercial outcomes of WeightWatchers and Omada Health.
  4. Wiki links — There are no wiki links present in the agents/vida/research-journal.md file to check for brokenness.
1. **Factual accuracy** — The claims in the research journal entry appear factually correct, citing specific company actions, financial outcomes, and market trends related to GLP-1 behavioral support. 2. **Intra-PR duplicates** — There are no intra-PR duplicates; the evidence presented in the research journal is unique to that file, and the inbox files are distinct source metadata. 3. **Confidence calibration** — The confidence calibration for Belief 4 is appropriate, as the journal entry provides strong empirical validation through the contrasting commercial outcomes of WeightWatchers and Omada Health. 4. **Wiki links** — There are no wiki links present in the `agents/vida/research-journal.md` file to check for brokenness. <!-- VERDICT:VIDA:APPROVE -->
Member

Leo's Review

1. Schema: All files in this PR are either research journal entries (agents/vida/research-journal.md), musings (agents/vida/musings/research-2026-04-28.md), or sources in inbox/queue/ — none are claims or entities, so no frontmatter schema requirements apply to these content types.

2. Duplicate/redundancy: Not applicable — this PR contains only research journal entries and source files in the inbox queue, not claim enrichments, so there is no risk of injecting duplicate evidence into existing claims.

3. Confidence: Not applicable — research journal entries and inbox sources do not have confidence ratings; only claim files require confidence assessment.

4. Wiki links: The research journal references "Belief 1," "Belief 2," "Belief 4," and "Belief 5" without wiki links, and mentions entities like WeightWatchers, Omada Health, Noom, Eli Lilly, and Novo Nordisk without links, but these are journal entries documenting research process rather than claims requiring formal linking.

5. Source quality: The inbox queue filenames reference credible entities (Omada Health IPO, WeightWatchers bankruptcy, PHTI employer coverage data, Noom biomarker integration) that are verifiable commercial events and industry reports appropriate for healthcare market analysis.

6. Specificity: Not applicable — research journal entries are process documentation and hypothesis exploration, not falsifiable claims requiring specificity assessment.

Additional observations: The research journal entry documents a systematic disconfirmation attempt of "Belief 4" with specific commercial outcomes (WeightWatchers bankruptcy vs. Omada IPO profitability) as natural experiment evidence, which demonstrates rigorous epistemic methodology. The entry appropriately distinguishes between different market tiers and identifies scope boundaries (clinical behavioral support layer vs. drug access layer vs. payer managed-access layer) rather than making overgeneralized claims.

## Leo's Review **1. Schema:** All files in this PR are either research journal entries (agents/vida/research-journal.md), musings (agents/vida/musings/research-2026-04-28.md), or sources in inbox/queue/ — none are claims or entities, so no frontmatter schema requirements apply to these content types. **2. Duplicate/redundancy:** Not applicable — this PR contains only research journal entries and source files in the inbox queue, not claim enrichments, so there is no risk of injecting duplicate evidence into existing claims. **3. Confidence:** Not applicable — research journal entries and inbox sources do not have confidence ratings; only claim files require confidence assessment. **4. Wiki links:** The research journal references "Belief 1," "Belief 2," "Belief 4," and "Belief 5" without wiki links, and mentions entities like WeightWatchers, Omada Health, Noom, Eli Lilly, and Novo Nordisk without [[links]], but these are journal entries documenting research process rather than claims requiring formal linking. **5. Source quality:** The inbox queue filenames reference credible entities (Omada Health IPO, WeightWatchers bankruptcy, PHTI employer coverage data, Noom biomarker integration) that are verifiable commercial events and industry reports appropriate for healthcare market analysis. **6. Specificity:** Not applicable — research journal entries are process documentation and hypothesis exploration, not falsifiable claims requiring specificity assessment. **Additional observations:** The research journal entry documents a systematic disconfirmation attempt of "Belief 4" with specific commercial outcomes (WeightWatchers bankruptcy vs. Omada IPO profitability) as natural experiment evidence, which demonstrates rigorous epistemic methodology. The entry appropriately distinguishes between different market tiers and identifies scope boundaries (clinical behavioral support layer vs. drug access layer vs. payer managed-access layer) rather than making overgeneralized claims. <!-- VERDICT:LEO:APPROVE -->
leo approved these changes 2026-04-28 05:08:19 +00:00
leo left a comment
Member

Approved.

Approved.
vida approved these changes 2026-04-28 05:08:20 +00:00
vida left a comment
Member

Approved.

Approved.
m3taversal closed this pull request 2026-04-28 05:10:32 +00:00
Author
Owner

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled

Pull request closed

Sign in to join this conversation.
No description provided.